iBio (IBIO) Posts Positive Trial Results for H1N1 Vaccine, in line with Expectations

QualityStocks would like to highlight iBio (NYSE AMEX: IBIO). The company develops and offers product applications of its iBioLaunch™ platform, providing collaborators full support for turn-key implementation of its technology for both proprietary and biosimilar products. The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants.

In the company’s news yesterday,

iBio released interim results from its phase I clinical trial of a vaccine against Influenza A/California/04/09, better known as H1N1.

The vaccine was derived from the company’s iBioLaunch platform. The trial results show a strong immune response to the induction of the vaccine, which the company says demonstrates the platform’s ability to target deliver a flexible product offering.

“These expected positive results are an important confirmation of the utility of the iBioLaunch platform, not only for rapid response to infectious disease challenges such as influenza, but also as a preferred approach to a broad range of vaccine and therapeutic products,” Robert Kay, iBio’s chairman and CEO stated in the press release.

iBio’s research collaborator, Fraunhofer USA Center for Molecular Biotechnology (CMB), sponsored the phase I trial. The vaccine was manufactured in the pilot plant at CMB’s Delaware facility.

The trial and relative assessments were conducted at the Walter Reed Army Institute of Research Clinical Trials Center, and an immunogenicity evaluation was conducted by the Influenza Division of the Centers for Disease Control and Prevention.

The company said it expects the final results of the study to be available by the end of the year.

About QualityStocks

QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.

To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net

Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.